CJC-1295 No DAC vs CJC-1295+Ipamorelin Blend
CJC-1295 No DAC is one of the two components inside the CJC-1295+Ipamorelin Blend, so this comparison contrasts single-compound sourcing with a fixed-ratio blend. The individual CJC-1295 No DAC vial (10 mg) allows independent dose control for GHRH-axis research. The blend vial (10 mg total) provides CJC-1295 No DAC alongside Ipamorelin at a fixed 1:1 ratio. The choice depends on protocol-design requirements.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Format | Single compound (10 mg CJC-1295 No DAC) | Two-compound blend (CJC-1295 No DAC 5 mg + Ipamorelin 5 mg) |
| Dose control | Independent: researcher sets CJC-1295 No DAC dose without constraint | Fixed 1:1 ratio: adjusting one compound changes the other proportionally |
| Receptor targets | GHRH receptor on anterior pituitary somatotrophs | GHRH receptor (CJC-1295) + ghrelin receptor GHS-R1a (Ipamorelin) |
| GH-release mechanism | Amplified GH pulse amplitude via GHRH-receptor engagement | Dual-axis: pulse-amplitude amplification (CJC-1295) + pulsatile release trigger (Ipamorelin) |
| Total vial mass | 10 mg | 10 mg |
| Reconstitution | Bacteriostatic water; lyophilised vial | Bacteriostatic water; lyophilised vial |
| Ronin catalog format | Single-compound lyophilised vial | Lyophilised blend vial |
How they differ in mechanism
CJC-1295 No DAC (also designated modified GRF 1-29) engages the growth-hormone-releasing-hormone receptor on anterior pituitary somatotrophs. Published studies describe prolonged GH and IGF-1 secretion, preservation of pulsatile release patterns, and normalisation of growth in GHRH-deficient models. The standalone vial allows the researcher to control CJC-1295 dose independently.
The CJC-1295+Ipamorelin Blend combines CJC-1295 No DAC (5 mg) with Ipamorelin (5 mg). Ipamorelin engages the ghrelin receptor as a selective GH secretagogue. The combination provides two complementary GH-release axes: GHRH-receptor-mediated pulse-amplitude amplification from CJC-1295, and ghrelin-receptor-mediated pulsatile GH release from Ipamorelin.
The standalone CJC-1295 No DAC vial provides one axis (GHRH receptor). The blend provides both axes at a fixed ratio. A researcher interested in GHRH-receptor pharmacology alone uses the standalone vial. A researcher interested in dual-axis GH modulation uses the blend.
How research has examined each
The CJC-1295 literature includes identification as a long-acting GHRH analogue (Jette et al., 2005), clinical pharmacology studies (Teichman et al., 2006), pulsatile-secretion characterisation (Ionescu et al., 2006), and growth normalisation in GHRH knockout models (Alba et al., 2006). The compound preserves physiological pulsatile GH secretion patterns during continuous stimulation.
The Ipamorelin literature spans selectivity characterisation, postoperative-ileus models, and GH-secretagogue pharmacology. The combination concept targets both the GHRH and ghrelin receptor arms of GH regulation. No published study examines the specific combination at the blend ratio.
The dual-axis concept has a pharmacological rationale but is not a published protocol replication. Researchers decide between single-axis dose control and dual-axis convenience based on their protocol requirements.
Stacking considerations in research contexts
Adding standalone CJC-1295 No DAC to a blend protocol would increase total CJC-1295 dose while maintaining the fixed Ipamorelin contribution, shifting the axis balance toward more GHRH-receptor stimulus. Researchers typically select one format rather than combining both.
Sourcing both at Ronin
The CJC-1295 No DAC vial page provides 10 mg as a single compound. The CJC-1295+Ipamorelin Blend page provides 10 mg total of the two-compound blend. Both ship as lyophilised peptide in glass vials with certificate-of-analysis documentation. Both are research-grade reagents.
Both compounds are also available together in the combined-formulation vial for researchers using the canonical fixed-ratio combination.
Frequently asked research questions
Is the CJC-1295 identical in both formats?
Yes. The CJC-1295 No DAC peptide (modified GRF 1-29) is the same GHRH analogue. The difference is mass (10 mg standalone versus 5 mg within the blend) and whether Ipamorelin is co-formulated.
What does Ipamorelin add?
Ipamorelin engages the ghrelin receptor (GHS-R1a) for selective pulsatile GH release. The blend provides dual-axis GH stimulation via both the GHRH and ghrelin receptor pathways.
Why choose the standalone vial?
Independent dose control. The researcher can use CJC-1295 alone or combine it with other compounds at chosen ratios.
Has the combination been studied?
No published study examines CJC-1295 + Ipamorelin at the blend ratio. Both have independent research literatures.
Are either approved for human use?
Neither is approved by the FDA or Health Canada. Both are research-grade reagents.
References
- Jette L et al. Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. [PMID 15817669]
- Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006. [PMID 16352683]
- Ionescu M et al. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006. [PMID 17018654]
- Alba M et al. Once-daily CJC-1295 normalizes growth in the GHRH knockout mouse. American Journal of Physiology, 2006. [PMID 16822960]
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. [PMID 9849822]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.